Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, et al. JAMA Oncology. 2019

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, et al. European Urology. 2018.

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, et al. Ann Oncol. 2017.

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. BJU Int. 2017.

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, et al. Sci Transl Med. 2015

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, et al. Lancet Oncol. 2015

Androgen receptor expression in circulating tumour cells from castratio0resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, et al. Br J Cancer. 2015

Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Attard G, et al. Clin Cancer Res. 2015

Tumor clone dynamics in lethal prostate cancer.

Carreira S, et al. Sci Transl Med. 2014

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, et al. Cancer Res. 2012

Selected publications

Treatment Resistance Group, UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK

  • Twitter Clean Grey